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Abstract 
BACKGROUND: Over the past decades, the study of the microenvironment of cancer has supported the 
hypothesis between inflammation and cancer. Previous studies have demonstrated a promising value of platelet-
to-lymphocyte (PLR) and neutrophil-to-lymphocyte ratio (NLR) as a systemic inflammatory response in prostate 
cancer. 
AIM: To evaluate their pre-biopsy values of PLR and NLR in predicting prostate cancer. 
MATERIAL AND METHODS: This is a diagnostic study with retrospective design. We included all benign 
prostatic hyperplasia (BPH) and prostate cancer (PCa) patients who underwent prostate biopsy in Adam Malik 
Hospital between August 2011 and August 2015. We used PSA value above 4 ng/dL as the threshold for the 
biopsy candidates. The relationship between pre-biopsy variables affecting the percentage of prostate cancer risk 
was evaluated, including age, prostate-specific antigen (PSA) level, and estimated prostate volume (EPV). The 
PLR and NLR were calculated from the ratio of related platelets or absolute neutrophil counts with their absolute 
lymphocyte counts. The values then analysed to evaluate their associations with the diagnosis of BPH and PCa. 
RESULTS: Out of 298 patients included in this study, we defined two groups consist of 126 (42.3%) BPH and 172 
PCa (57.7%) patients. Mean age for both groups are 66.36 ± 7.53 and 67.99 ± 7.48 years old (p = 0.64), 
respectively. There are statistically significant differences noted from both BPH and PCa groups in terms of PSA 
(19.28 ± 27.11 ng/dL vs 40.19 ± 49.39 ng/dL), EPV  (49.39 ± 23.51 cc vs 58.10 ± 30.54 cc), PLR (160.27 ± 98.96 
vs 169.55 ± 78.07), and NLR (3.57 ± 3.23 vs 4.22 ± 2.59) features of both BPH and PCa groups respectively (p < 
0.05). A Receiver Operating Characteristics (ROC) analysis was performed for PLR and NLR in analysing their 
value in predicting prostate cancer. The Area Under the Curve (AUC) of PLR is 57.9% with a sensitivity of 56.4% 
and specificity of 55.6% in the cut-off point of 143 (p = 0.02). The NLR cut-off point of 3.08 gives 62.8% AUC with 
64.5% sensitivity and 63.5% specificity. These AUCs were comparable with the AUC of PSA alone (68.5%). We 
performed logistic regression between PSA, PLR, and NLR with result in the exclusion of PLR if calculated 
conjunctively. Therefore, NLR has a promising performance in predicting PCa in patients with PSA above 4 ng/dL 
(OR = 3.2; 95% CI: 1.96-5.11). We found as many as 80 (63.5%) patients with benign biopsy results with negative 
NLR value in this study. 
CONCLUSION: NLR has promising value in predicting prostate cancer. A further prospective study in validating 
its diagnostic value was needed. 
 
 
 
 
 
 
Introduction 
 
Prostate cancer (PCa) is the second most 
common cancer worldwide. It accounts for more than 
15% of cancer in men with ongoing rising clinical 
relevancies. About 70% of them occurs in the 
developed country [1], [2]. Trans Rectal Ultrasound 
Guided procedure of prostate biopsy remains the gold 
standard in most countries in the diagnosis of prostate 
cancer. Since the biopsy is mostly office procedure 
and not only uncomfortable but also associated with 
significant complications, various non-invasive 
strategies have been invented to prevent unnecessary 
biopsy [3]. 
Serum Prostate Specific Antigen (PSA) has 
been used as the screening standard for patients in 
suspicion of prostate cancer. PSA value of more than 
4 ng/ml has been considered the threshold to biopsy 
in most countries [1], [2], [4], [5], [6], [7], [8]. But, 
recent meta-analyses showed a positive predictive 
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value of PSA above 4 ng/ml is only 25% [6]. Besides, 
the invasive prostate biopsy may still miss some 
percentage of cancer, given that up to 20% of men will 
have prostate cancer in a repeated biopsy [9]. Various 
imaging and bio-molecular marker have been 
suggested to increase diagnostic accuracy, but none 
of these methods is available for widespread use, 
either due to the availability or even high-cost issues 
[2], [9]. 
Over the past decades, our study of the 
microenvironment of cancer has supported Virchow’s 
hypothesis of the relationship between inflammation 
and cancer. Inflammatory markers have been 
associated with more aggressive disease [7], [10]. 
Study of Cihan et al., in 2013 showed that values of 
lymphocytes, neutrophils, and white blood cells are 
significantly lower in PCa patients with statistically 
significant difference noted in lymphocytes value 
compared to healthy controls. Their ease of 
assessment brings the suggestion to use it in 
combination with other parameters in predicting the 
diagnosis of prostate cancer [3]. Many follow-up 
studies had been using neutrophil-to-lymphocyte ratio 
in fields of predicting diagnosis, prognosis, and 
recurrence after definitive management [2], [5], [11], 
[12], [13], [14], [15]. 
Though small in numbers, previous studies 
also demonstrated the promising value of platelet-to-
lymphocyte (PLR) in prostate cancer. Kaynaret al. 
found an increased level of PLR in PCa compared 
with that in benign prostatic hyperplasia (BPH) with 
PSA value greater than 10 ng/ml [16]. A statistically 
significant higher PLR in PCa compared to BPH 
patients was also demonstrated by Yuksel et al., in 
2015 [6]. 
According to our knowledge, there is still no 
data on the use of NLR and PLR as predictors of PCa 
in Indonesia. Therefore, this study is conducted to 
evaluate its pre-biopsy value in predicting PCa.  
 
 
Material and Methods 
 
Population of Study 
This is a diagnostic study with retrospective 
design. All patients who underwent prostate biopsy in 
Adam Malik General Hospital between August 2011 
and August 2015 were included. Data related to 
prostate cancer prediction factors were collected, and 
their relationship with malignant pathology was 
analysed. The factors included were: age, serum PSA 
value, and estimated prostate volume (EPV). The 
routine blood count collected to calculate the NLR and 
PCR were the recent results right before the biopsy 
procedure was performed. Histopathology of the 
biopsy specimen was applied as the gold standard of 
PCa diagnosis. Patients with irrelevant and 
incomplete data were excluded from the study. 
 
Variables 
Serum PSA was collected from recent 
laboratory results just before biopsy procedures were 
performed. We collected EPVs from their initial Trans-
Abdominal Ultrasound (TAUS) of the prostate. 
Prostate was measured in 3-dimensional aspects, and 
its volume was estimated with the modified ellipsoid 
formulation in cm
3
 (0.523 [(length x width x height)]. 
NLR and PLR value are acquired from the direct 
division of absolute neutrophil count or platelets count 
with their absolute lymphocyte count. 
 
Analysis 
Input and data analysis was performed using 
SPSS ver 20.0 software. Data will be divided into two 
groups according to their histopathology of prostate 
biopsy, the BPH and PCa group. A pathology of 
prostatitis will be excluded. Data related to PCa 
prediction such as routine blood count, NLR, and PLR 
of each group will be distributed in a frequency table 
and analysed for their value in predicting biopsy 
results with bivariate analysis. A p value of < 0.05 ( = 
5%) was considered statistically significant. Logistic 
regression will be performed to multivariate analysed 
EPV, PSA, NLR, and PLR as predictive factors of 
prostate biopsy. 
 
 
Results 
 
Characteristics and Bivariate Analysis 
As many as 298 patients consisting of 126 
(42.3%) BPH and 172 PCa (57.7%) patients are 
included in this study. Mean age for both groups are 
66.36 ± 7.53 and 67.99 ± 7.48 years old (p = 0.64), 
respectively. Patients characteristics and laboratory 
values are shown (Table 1). 
Table 1: Patients Characteristics and Hematologic Parameters 
Parameters BPH (n = 126) 
Mean ± SD 
(Median) 
PCa (n = 172) 
Mean ± SD 
(Median) 
p 
Age (years) 66.36 ± 7.53 67.99 ± 7.48 0.64* 
PSA (ng/dL) 19.28 ± 27.11 40.19 ± 49.39 < 0.0001* 
EPV (cm
3
) 49.39 ± 23.51 58.10 ± 30.54 0.02* 
Hb 12.99 ± 2.00 (13.20) 12.95 ± 2.01 (13.10) 0.754** 
Leucocytes Count (x10
3
/mm
3
) 8.67 ± 3.45 (8.11) 9.19 ± 3.29 (8.46) 0.1** 
Absolute Neutrophil Count 
(x10
3
/mm
3
) 
6.09 ± 3.19 (5.45) 7.54 ± 3.64 (6.92) < 0.0001** 
Absolute Lymphocyte Count 
(x10
3
/mm
3
) 
2.09 ± 0.83 (2.02) 2.00 ± 0.76 (1.87) 0.29** 
Platelets Count (x10
3
/mm
3
) 286.16 ± 112.24 
(266) 
311.61 ± 120.81 (294) 0.049** 
NLR 3.57 ± 3.23 (2.54) 4.22 ± 2.59 (3.67) < 0.0001** 
PLR 160.27 ± 98.96 
(128.13) 
169.55 ± 78.07 
(151.28) 
0.02** 
*T-test **Mann-Whitney Test. 
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Comparing the laboratory results of both 
groups, there were statistically significant differences 
noted from PSA (19.28 ± 27.11 vs 40.19 ± 49.39), 
EPV (49.39 ± 23.51 vs 58.10 ± 30.54), NLR (3.57 ± 
3.23 vs 4.22 ± 2.59), and PLR (160.27 ± 98.96 vs 
169.55 ± 78.07) in each bivariate analysis. 
 
NLR, PLR, and PSA 
We then performed a Receiver Operating 
Characteristics (ROC) analysis to define the Area 
Under Curve (AUC) of NLR and PLR in predicting 
prostate cancer (Figure 1 and Table 2).  
 
Figure 1: The ROC Curves of NLR, PLR, and PSA  
 
The NLR cut-off point of 3.08 gives 62.8% 
AUC with 64.5% sensitivity and 63.5% specificity. The 
AUC of PLR is 57.9% with a sensitivity of 56.4% and 
specificity of 55.6% in the cut-off point of 143 (p = 
0.02). 
Table 2: The AUC of NLR, PLR, and PSA 
Parameters AUC p 
NLR 62.8% < 0.0001 
PLR 57.9% 0.02 
PSA 68.5% < 0.0001 
 
 
Multivariate Analysis 
We performed logistic regression between 
EPV, PSA, PLR, and NLR with results described in 
Table 2. We used the cut-off value of NLR (3.08) and 
PLR (143) as retrieved from ROC analysis before to 
be included as categorical variables in the regression. 
PLR was excluded from the regression as it was not 
statistically significant if analysed conjunctively. Thus, 
the equation leaves NLR as a single most important 
systemic inflammatory biomarker in predicting 
prostate cancer (Table 3). 
Table 3: Multivariate Analysis: Logistic Regression 
Variables OR 95% CI p 
EPV 1.012 1.002 – 1.022 0.21 
NLR (≥ 3.08) 2.856 1.734 – 4.702 < 0.0001 
PLR (≥ 143)* 1.152 0.648 – 2.049 0.63 
PSA 1.016 1.007 – 1.025 < 0.0001 
*before excluded in Backward: LR method. 
NLR, PLR, and IPCRC: A Subgroup 
Analysis 
We asked for permission from the preceding 
authors of Indonesian Prostate Cancer Risk 
Calculator (IPCRC) and calculated its value from 98 
randomised patients consist of 45 (45.92%) BPH and 
53 (54.08%) PCa.  
 
Figure 2: The ROC Curves of PLR and IPCRC Score 
 
We found a comparable value between NLR 
and PLR with IPCRC in predicting prostate cancer 
(AUC of 75.3%, 67.6%, and 68.4%, respectively) with 
a statistically significant difference was noted between 
each value (p < 0.05) as shown in Figure 2 and Table 
4.  
Table 4: The AUC of NLR, PLR, and IPCRC 
Parameters AUC p 
NLR 75.3% < 0.0001 
PLR 67.6% 0.003 
IPCRC 68.5% 0.002 
 
 
 
Discussion 
 
The body response to cancer parallels with 
inflammation and wound healings. In 1863, Rudolf 
Virchow noted leucocytes in neoplastic tissues and 
suggested a connection between inflammation and 
cancer. He suggested that the “lymphoreticular 
infiltrate” reflected the origin of cancer at sites of 
chronic inflammation. Tumour-infiltrating lymphocytes 
may contribute to cancer growth and spread, and the 
immunosuppression associated with malignant 
disease. In his review in 2001, Balkwill et al., still 
mention the theory of “Tumours: wounds that do not 
heal” [10] previously showed by Dvorak in 1986 [10]. 
This theory showed how wound healing and tumour 
stroma formation share many important features. 
Wound healing is usually self-limiting, but tumours 
secrete a vascular permeability factor, vascular 
endothelial growth factor (VEGF), that can lead to 
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persistent extravasation of fibrin and fibronectin and 
continuous generation of the extracellular matrix. 
Platelets in wounds are a critical source of cytokines, 
especially transforming growth factor  (TGF-) and 
VEGF. Platelet release of such factors may also play 
an important role in angiogenesis. Also, malignant 
cells themselves secrete proinflammatory cytokines 
[10]. 
Though inflammatory markers such as 
lymphocytes were mentioned in previous studies, not 
all markers are incoherent with every cancer. 
Leucocytes, mainly lymphocytes, is the most 
prominent marker in many cancers, but not in PCa. 
Study of Cihan Y, et al. showed that patient with PCa 
had a lower level of lymphocytes, neutrophils, and a 
higher level of monocytes with a significant difference 
in lymphocyte count, compared to healthy controls [3]. 
McDonald et al., also found that lymphocytes count is 
significantly lower in patients with elevated PSA 
compared with patients with PSA below 4 ng/ml [4]. 
Though this study found that the absolute lymphocyte 
counts of PCa patients are lower, the difference was 
not statistically significant compared with a benign 
group (2.09 ± 0.83 vs 2.00 ± 0.76; p = 0.23). 
As supported by previous studies, we 
calculated the NLR values of both groups and found a 
significant difference of the value between PCa and 
BPH groups (4.22 ± 2.59 vs 3.57 ± 3.23; p < 0.0001). 
Gokce et al., in a larger population, also found the 
same significant results of the difference between 
both groups (p = 0.002). McDonald et al., in his study, 
found a correlation between increasing PSA and NLR 
value (ORmultiv = 1.14; 95% CI, 1.03-1.26), after 
adjustment for age, smoking, body mass index, 
education, race, co-morbidities, and use of 
medications [4]. These findings are also coherent with 
the recent study of Oh JJ et al., and Kawahara et al., 
in 2015 [5], [9]. 
In this study, though we found a significant 
difference of platelets count with no statistical 
difference in lymphocyte count between both groups, 
the ratio of PLR value gives the event more significant 
difference (p = 0.02). A similar result of this study also 
showed by Yuksel et al., where a significant 
intergroup statistical difference was found for PLR (p = 
0.041) but not for lymphocyte count (p > 0.05) [6]. This 
also supported by the study of Li et al., who found a 
statistical difference of PLR value in PCa and 
normal/BPH patient (p < 0.05). 
Our multivariate analysis revealed that not 
only EPV and PSA, but NLR was also an independent 
biomarker in predicting prostate biopsy (OR 2.856; 
95%CI 1.734 – 4.702). PLR was excluded in the 
analysis as it is not significant statistically in the 
concurrent analysis. Same results were stated in 
Kawahara et al. who found that not only free to total 
PSA ratio (HR = 3.13) but also NLR (HR = 2.21) was 
an independent risk factor for prostate cancer [5]. In 
another study of Oh JJ et al., in their multivariate 
analyses, a higher NLR was significantly associated 
with prostate cancer detection after adjusting for other 
factors (OR = 1.372, p = 0.038). An increased 
accuracy noted from 0.712 to 0.725 in the addition of 
NLR (p = 0.005) in the multivariate model for prostate 
cancer detection [9]. Thus, we can conclude that NLR 
is increasing in prostate cancer. 
IPCRC has been widely used in Indonesia as 
a clinical calculator to predict the diagnosis of PCa. In 
a subgroup analysis, we compared the NLR and PLR 
value with IPCRC and analysed their AUC with ROC 
analysis and found a comparable result of NLR with 
IPCRC. NLR surprisingly has a comparable AUC with 
IPCRC (75.3% vs 68.5%). From these findings, we 
can conclude that further validation is mandatory. 
Increasing NLR can be part of the calculation in 
predicting prostate cancer. 
In conclusion, NLR is thus likely elevated in 
patients with prostate cancer. Accordingly, NLR, with 
or without combination with PSA, may function as a 
new systemic inflammatory biomarker in predicting 
prostate biopsy results. To be applied as routine 
testing and to selectively decide candidates for 
prostate biopsy in a patient with PSA value more than 
4 ng/ml, further prospective trial and validation is 
mandatory. 
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